Fig. 3From: Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosisClinical assessments in patients with complete resolution of bone marrow fibrosis. a Haemoglobin levels, b white blood cell count and c change in spleen sizeBack to article page